CN1151155C - 1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物 - Google Patents

1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物

Info

Publication number
CN1151155C
CN1151155C CNB988049872A CN98804987A CN1151155C CN 1151155 C CN1151155 C CN 1151155C CN B988049872 A CNB988049872 A CN B988049872A CN 98804987 A CN98804987 A CN 98804987A CN 1151155 C CN1151155 C CN 1151155C
Authority
CN
China
Prior art keywords
group
carbon atoms
phenyl
straight
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988049872A
Other languages
English (en)
Chinese (zh)
Other versions
CN1255133A (zh
Inventor
H
H·哈宁
U·尼沃纳
U·罗森特雷特
T·申克
ϣ
J·克尔德尼希
E·比肖夫
��Ĭ����
K·H·施莱默
H·许茨
G·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN1255133A publication Critical patent/CN1255133A/zh
Application granted granted Critical
Publication of CN1151155C publication Critical patent/CN1151155C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988049872A 1997-03-11 1998-02-26 1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物 Expired - Fee Related CN1151155C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19709877.0 1997-03-11
DE19709877A DE19709877A1 (de) 1997-03-11 1997-03-11 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate

Publications (2)

Publication Number Publication Date
CN1255133A CN1255133A (zh) 2000-05-31
CN1151155C true CN1151155C (zh) 2004-05-26

Family

ID=7822900

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988049872A Expired - Fee Related CN1151155C (zh) 1997-03-11 1998-02-26 1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物

Country Status (17)

Country Link
US (1) US6174884B1 (https=)
EP (1) EP0973774B1 (https=)
JP (1) JP2001514638A (https=)
KR (1) KR20000076124A (https=)
CN (1) CN1151155C (https=)
AT (1) ATE231509T1 (https=)
AU (1) AU727615B2 (https=)
BR (1) BR9807995A (https=)
CA (1) CA2283211A1 (https=)
DE (2) DE19709877A1 (https=)
DK (1) DK0973774T3 (https=)
ES (1) ES2191294T3 (https=)
HU (1) HUP0001805A3 (https=)
IL (1) IL131450A0 (https=)
NZ (1) NZ337724A (https=)
RU (1) RU2219180C2 (https=)
WO (1) WO1998040384A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
WO2002009713A2 (de) * 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
EP1343506A1 (de) * 2000-12-19 2003-09-17 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
JP2004525890A (ja) * 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
AU2002366440A1 (en) * 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CN100397023C (zh) * 2003-01-04 2008-06-25 胡云北 黄磷废渣载热量及反应尾气发热量的回收与综合利用方法
EP1601675A1 (en) * 2003-03-04 2005-12-07 ALTANA Pharma AG Purin-6-one-derivatives
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
AU2004268387A1 (en) * 2003-08-28 2005-03-10 Nycomed Gmbh Composition comprising a pulmonary surfactant and a PDE2 inhibitor
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
AU2005219517A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CN101397299B (zh) * 2007-09-29 2011-11-16 温州大学 一种吡唑[3,4-d]嘧啶酮的合成方法
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
DK3126361T3 (da) 2014-04-01 2020-01-02 Pfizer Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
PL3177624T3 (pl) 2014-08-06 2019-09-30 Pfizer Inc. Związki imidazopirydazynowe
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2016179059A1 (en) * 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
EP3766885B1 (en) 2015-06-17 2022-05-25 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
SG11201806383TA (en) 2016-02-23 2018-09-27 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018002760A1 (en) 2016-07-01 2018-01-04 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
ES2967489T3 (es) * 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
RU2019109039A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
RU2019144010A (ru) 2017-06-08 2021-07-13 Мерк Шарп И Доум Корп. Пиразолопиримидиновые ингибиторы pde9
BR112019026955A2 (pt) 2017-06-22 2020-06-30 Pfizer Inc. derivados de di-hidro-pirrolo-piridina
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
EP4219464A1 (en) 2018-03-23 2023-08-02 Pfizer Inc. Piperazine azaspiro derivaves
USD1029414S1 (en) * 2021-01-19 2024-05-28 Averia Electronics, Inc. Wearable light emitting module with a removable band
USD1021287S1 (en) * 2021-01-19 2024-04-02 Averia Electronics, Inc. Wearable light emitting module with a removable band
EP4297868A4 (en) 2021-02-23 2025-01-08 Hoth Therapeutics, Inc. USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) * 1965-01-12 Certificate of correction
US3211732A (en) 1965-10-12 Pyrazolob:x-d]pyrlil/hdines
DE1153023B (de) 1960-05-11 1963-08-22 Ciba Geigy Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3,4-d] pyrimidinen
CH398626A (de) * 1960-05-11 1966-03-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
CH633297A5 (de) 1977-09-16 1982-11-30 Sandoz Ag Verfahren zur herstellung von fluorenphosphoniten.
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
CA2133346A1 (en) * 1992-04-21 1993-10-28 Shri Niwas 7-disubstituted-methyl-4-oxo-3h,5h-pyrrolo[3,2-d]pyrimidine and pharmaceutical uses and compositions containing the same
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
CZ280697A3 (cs) 1995-03-10 1998-04-15 Sanofi Pharmaceuticals, Inc. 6 aryl-pyrazolo(3,4-d)pyrimidin-4-ony a kompozice je obsahující, a způsob jejich použití

Also Published As

Publication number Publication date
HUP0001805A2 (hu) 2000-11-28
DK0973774T3 (da) 2003-05-05
NZ337724A (en) 2000-08-25
US6174884B1 (en) 2001-01-16
IL131450A0 (en) 2001-01-28
AU6824098A (en) 1998-09-29
BR9807995A (pt) 2000-03-08
ATE231509T1 (de) 2003-02-15
EP0973774B1 (de) 2003-01-22
CN1255133A (zh) 2000-05-31
HUP0001805A3 (en) 2002-09-30
DE59807011D1 (de) 2003-02-27
KR20000076124A (ko) 2000-12-26
AU727615B2 (en) 2000-12-14
CA2283211A1 (en) 1998-09-17
JP2001514638A (ja) 2001-09-11
RU2219180C2 (ru) 2003-12-20
WO1998040384A1 (de) 1998-09-17
EP0973774A1 (de) 2000-01-26
HK1028035A1 (en) 2001-02-02
ES2191294T3 (es) 2003-09-01
DE19709877A1 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
CN1151155C (zh) 1,5-二氢-吡唑并[3,4-d]-嘧啶酮衍生物
CN1036263C (zh) 取代的唑类化合物的制备方法
CN1032203C (zh) 制备取代2-吡啶酮和吡啶-2-硫酮的方法
CN1031570C (zh) 吡唑并吡啶化合物的制备方法
CN1165536C (zh) 与六元杂环稠合的取代的吡唑衍生物
CN1075070C (zh) 取代的氮－及二氮杂环庚烷及－环辛烷化合物及其用途
CN1218471A (zh) 咔啉衍生物
CN1191255C (zh) 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN1216531A (zh) 用作内皮缩血管肽受体拮抗剂的吲哚衍生物
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1890218A (zh) 微管蛋白抑制剂
CN1675214A (zh) 具有抗增殖活性的嘧啶并化合物
CN1215051A (zh) α－取代苯基丙酸衍生物及含这种化合物的药品
CN86100090A (zh) 萘衍生物的制备方法
CN1036004C (zh) 镇痛羧酸酰胺衍生物的制备方法
CN1069728A (zh) 美拉德反应抑制剂
CN1159303C (zh) 单环β-内酰胺类抗生素衍生物的中间体的制备方法
CN1413205A (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN1138583A (zh) 9-取代的2-(2-正烷氧基苯基)-嘌呤-6-酮类化合物
CN1169797C (zh) 抗病毒的嘧啶二酮衍生物及其制备方法
CN1137039A (zh) 抗神经变性活性的10-氨基脂族基二苯并[b,f]噁庚英
CN1254334A (zh) 新颖的对苯二甲酰胺衍生物
CN1433410A (zh) 具有3－羟基色烯－4－酮结构的cdk抑制剂
CN1049161A (zh) 具有血清素2-受体拮抗活性的杂环化合物
CN1257864A (zh) 新的咪唑啉化合物、其制备方法和含有它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: International Day of publication

Correct: 19980917

False: 19980902

Number: 21

Page: 447

Volume: 20

CI03 Correction of invention patent

Correction item: International Day of publication

Correct: 19980917

False: 19980902

Number: 21

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: DATE OF THE INTERNATIONAL PROCLAMATION; FROM: 1998.9.2 TO: 1998.9.17

ERR Gazette correction

Free format text: CORRECT: DATE OF THE INTERNATIONAL PROCLAMATION; FROM: 1998.9.2 TO: 1998.9.17

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee